Navigation Links
Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology
Date:1/3/2012

PLANTATION, Fla. and MOSCOW, Jan. 3, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC, a Maxwell Biotech portfolio company, jointly announced an agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line. The monoclonal antibody will be engineered by GBI's collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in clinical trials as a potential treatment for renal cell carcinoma.

"This is an exciting project for us," noted Muctarr Sesay, PhD, Vice President of Process Development at GBI. "It truly represents 'one-stop-shopping' for our clients because we can take a client's cDNA, engineer the cell line with the help of one of our collaborative partners, Rafagen, who will provide us with three stable, high-producing clones, then we'll evaluate the clones and select the highest producer, create a Research Cell Bank and start manufacturing the antibody of interest."

"Our drug candidate OM-RCA-001 is a humanized monoclonal antibody and establishing a high producing cell line and creating a cell bank is one of the key stages of the product's development. We are pleased to partner with GBI in this, since GBI is known for its high quality services in this line of work," said Nikolay Golub, PhD, Project Manager at Maxwell Biotech Group where OncoMax is a portfolio company. "OM-RCA-001 blocks a specific target of kidney tumor cells, affecting the mechanisms of tumor progression and resistance. If all the clinical trials are successful we will have a novel biopharmaceutical that can be prescribed both as first-line treatment and as treatment in the second and subsequent lines after failure of other types of targeted therapy." 

About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies. For more information, please visit http://www.goodwinbio.com/.

About OncoMax LLC
OncoMax is a private biotechnological Russian company founded by Maxwell Biotech Group and funded by the Maxwell Biotech Venture Fund in 2010, a participant in the Technology Platform "Medicine of the Future" program and resident of the Skolkovo Innovation Center with a grant award from the Skolkovo Foundation. The mission of OncoMax is to develop and commercialize innovative therapies and diagnostics for oncology diseases. For more information, please visit: http://www.oncomax.com/.

About Maxwell Biotech Group
Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives, relying on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

MBG is investing in product development companies specializing in selected therapeutic and medical device categories. To date, MBG has established the portfolio companies of OncoMax (oncology), NeuroMax (CNS), MetaMax (oncology & metabolic diseases), Infectex (infectious diseases), CardioNova (cardiovascular diseases) and Photonics (novel lasers for medicine and dentistry). Products in these companies originated either from Russian scientists or were licensed for commercialization in Russia from international biopharma companies. For more information, please visit http://www.maxwellbio.com/.

For more information, please contact:

Goodwin Biotechnology:

Dave Cunningham

Director of Marketing

(954) 327-9639

DCunningham@goodwinbio.com

OncoMax:

Dr. Nikolay Golub

Project Manager
tel. +7 (495) 411-6992
golub@oncomax.ru

 


'/>"/>
SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
2. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
3. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
4. Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
5. Medical Marijuana Inc. to Acquire Biotechnology Company PharmaSphere, LLC from Converted Organics
6. Active Pharmaceutical Ingredients (APIs) in the Americas Market to 2016 - Growth in Biotechnology and Generic Segments and the Pharmaceutical Patent Cliff will Shape the Landscape
7. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
8. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
9. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
10. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
11. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... the only authorized OSHA Training Institute Education Center headquartered in Northern California, has ... workers from extreme heat at their worksites. Employers with workers exposed to ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):